Latest News about NVS
Recent news which mentions NVS
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery
January 08, 2024
From Benzinga
Voyager Therapeutics Stock Tanked After-Hours - Here's Why
January 04, 2024
From Benzinga
From InvestorPlace
From Benzinga
Why Is Neurology Focused Cingulate Stock Trading Higher Today?
December 28, 2023
From Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
From InvestorPlace
These 3 Big Pharma Stocks Are Making Big Plays With AI
December 22, 2023
From Motley Fool
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
From Benzinga
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
From Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
December 19, 2023
From Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
December 17, 2023
From InvestorPlace
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
From Benzinga
Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease
December 11, 2023
Tickers
NVS
From Benzinga
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
From Motley Fool
Novartis' Rare Blood Disorder Therapy Scores FDA Approval
December 06, 2023
Tickers
NVS
From Benzinga
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
From Benzinga
Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy
November 28, 2023
From MarketWatch
3 Healthcare Stocks to Pick Up Before the Year-End Rally
November 28, 2023
From InvestorPlace
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
November 16, 2023
From Motley Fool
Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment
November 13, 2023
From MarketWatch
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 05, 2023
From Motley Fool
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
October 30, 2023
Tickers
NVS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.